Insulin-like growth factor binding protein-7 concentrations in chronic heart failure: Results from the EMPEROR programme.
João Pedro FerreiraMilton PackerNaveed SattarJaved ButlerSandra González MaldonadoMarina Panova-NoevaMikhail SuminSerge MassonStuart J PocockStefan D AnkerFaiez ZannadJames L JanuzziPublished in: European journal of heart failure (2024)
Across the entire left ventricular EF spectrum in the EMPEROR Programme, concentrations of the senescence-associated biomarker IGFBP7 were associated with higher risk clinical status and predicted adverse cardio-renal outcomes even in models adjusted for conventional biomarkers. Empagliflozin did not significantly affect IGFBP7 levels over time.
Keyphrases
- binding protein
- left ventricular
- study protocol
- heart failure
- dna damage
- endothelial cells
- acute myocardial infarction
- ejection fraction
- hypertrophic cardiomyopathy
- randomized controlled trial
- cardiac resynchronization therapy
- clinical trial
- stress induced
- type diabetes
- metabolic syndrome
- growth hormone
- adipose tissue
- adverse drug
- acute coronary syndrome
- weight loss
- double blind